JP2017529859A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529859A5 JP2017529859A5 JP2017517098A JP2017517098A JP2017529859A5 JP 2017529859 A5 JP2017529859 A5 JP 2017529859A5 JP 2017517098 A JP2017517098 A JP 2017517098A JP 2017517098 A JP2017517098 A JP 2017517098A JP 2017529859 A5 JP2017529859 A5 JP 2017529859A5
- Authority
- JP
- Japan
- Prior art keywords
- single nucleotide
- breast cancer
- risk
- female subject
- linkage disequilibrium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 67
- 239000002773 nucleotide Substances 0.000 claims description 61
- 125000003729 nucleotide group Chemical group 0.000 claims description 61
- 206010006187 Breast cancer Diseases 0.000 claims description 54
- 208000026310 Breast neoplasm Diseases 0.000 claims description 54
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 31
- 238000012502 risk assessment Methods 0.000 claims description 27
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 230000002068 genetic effect Effects 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 7
- 239000012830 cancer therapeutic Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 5
- 102000015694 estrogen receptors Human genes 0.000 claims description 5
- 108010038795 estrogen receptors Proteins 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 4
- 238000003500 gene array Methods 0.000 claims description 4
- 238000001574 biopsy Methods 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000035606 childbirth Effects 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 230000009247 menarche Effects 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 210000005075 mammary gland Anatomy 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014903898 | 2014-09-30 | ||
| AU2014903898A AU2014903898A0 (en) | 2014-09-30 | Methods for assessing the risk of developing breast cancer | |
| PCT/AU2015/050583 WO2016049694A1 (en) | 2014-09-30 | 2015-09-29 | Methods for assessing risk of developing breast cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529859A JP2017529859A (ja) | 2017-10-12 |
| JP2017529859A5 true JP2017529859A5 (enExample) | 2018-11-08 |
| JP6820838B2 JP6820838B2 (ja) | 2021-01-27 |
Family
ID=55629155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517098A Expired - Fee Related JP6820838B2 (ja) | 2014-09-30 | 2015-09-29 | 乳癌発症リスクを評価する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10920279B2 (enExample) |
| EP (1) | EP3201360A4 (enExample) |
| JP (1) | JP6820838B2 (enExample) |
| KR (1) | KR102334702B1 (enExample) |
| CN (1) | CN107002138B (enExample) |
| AU (2) | AU2015327756B2 (enExample) |
| CA (1) | CA2962691C (enExample) |
| IL (1) | IL251376B (enExample) |
| MX (1) | MX392267B (enExample) |
| SG (1) | SG11201702416YA (enExample) |
| WO (1) | WO2016049694A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2468901B1 (en) | 2005-11-29 | 2017-04-05 | Cambridge Enterprise Limited | Markers for breast cancer |
| DK2438193T3 (en) | 2009-06-01 | 2015-10-19 | Genetic Technologies Ltd | Methods for assessing the risk of breast cancer |
| CA2962691C (en) | 2014-09-30 | 2023-05-23 | Genetic Technologies Limited | Methods for assessing risk of developing breast cancer |
| US20200102617A1 (en) * | 2017-01-24 | 2020-04-02 | Genetic Technologies Limited | Improved Methods For Assessing Risk of Developing Breast Cancer |
| US12577622B2 (en) | 2017-06-02 | 2026-03-17 | Myriad Genetics, Inc. | Detecting cancer risk |
| CA3078756A1 (en) * | 2017-10-13 | 2019-04-18 | Genetic Technologies Limited | Methods of assessing risk of developing breast cancer |
| CN108060229A (zh) * | 2017-12-27 | 2018-05-22 | 沃森克里克（北京）生物科技有限公司 | 一种TERT基因rs10069690位点SNP核酸质谱检测方法 |
| CN110628912A (zh) * | 2019-11-06 | 2019-12-31 | 上海韦翰斯生物医药科技有限公司 | 检测多态性的引物及方法 |
| KR102169699B1 (ko) * | 2019-12-27 | 2020-10-23 | 주식회사 클리노믹스 | 유전자 검사를 위한 맞춤형 유전자칩 및 이의 제작 방법 |
| KR20230019872A (ko) * | 2020-05-27 | 2023-02-09 | 지네틱 테크놀로지스 리미티드 | 코로나바이러스 감염에 대한 중증 반응의 발생 위험을 평가하는 방법 |
| CN112687330A (zh) * | 2020-12-29 | 2021-04-20 | 北京易奇科技有限公司 | 一种乳腺癌患者携带胚系致病变异的风险预测系统 |
| CN114283883B (zh) * | 2021-12-27 | 2022-11-22 | 上海华测艾普医学检验所有限公司 | 基于分子标记的用于肝癌筛查和风险预测的系统及应用 |
| US20250149176A1 (en) * | 2023-11-08 | 2025-05-08 | Optum Services (Ireland) Limited | Model-based risk prediction and treatment pathway prioritization |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54147035A (en) | 1978-05-10 | 1979-11-16 | Minolta Camera Co Ltd | Tessar type photographic lens placed behind aperture |
| US4240608A (en) | 1979-11-02 | 1980-12-23 | Acf Industries, Incorporated | Controlled float seat arrangement for expanding gate valves |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| WO1995011995A1 (en) | 1993-10-26 | 1995-05-04 | Affymax Technologies N.V. | Arrays of nucleic acid probes on biological chips |
| JP4540754B2 (ja) | 1996-06-04 | 2010-09-08 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | Ｐｃｒ中のハイブリダイゼーションのモニタリング |
| AU723400B2 (en) | 1996-11-07 | 2000-08-24 | Oklahoma Medical Research Foundation | Diagnostic assay for breast cancer susceptibility |
| MXPA01005513A (es) | 1998-12-02 | 2003-07-14 | Dna Sciences Inc | Metodos para reducir la variacion en estudios de tratamiento utilizando genotipificacion. |
| US20020123095A1 (en) | 1999-10-20 | 2002-09-05 | Pe Corporation (Ny) | Estrogen receptor alpha variants and methods of detection thereof |
| EP1305446A4 (en) | 2000-07-25 | 2004-10-06 | Dz Genes Llc | DIAGNOSIS OF ECNOS PROMOTER POLYMORPHISMS |
| US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US20030092019A1 (en) | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| AU785425B2 (en) | 2001-03-30 | 2007-05-17 | Genetic Technologies Limited | Methods of genomic analysis |
| AU2002322775A1 (en) | 2001-07-27 | 2003-02-17 | The Regents Of The University Of California | Stk15 (stk6) gene polymorphism and methods of determining cancer risk |
| US7529685B2 (en) | 2001-08-28 | 2009-05-05 | Md Datacor, Inc. | System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data |
| EP2135960A1 (en) | 2001-09-19 | 2009-12-23 | Intergenetics Incorporated | Genetic analysis for stratification of cancer risk by determining the allelic profile of the VDR-ApaI and CYP11B2 genes |
| US20040023237A1 (en) | 2001-11-26 | 2004-02-05 | Perelegen Sciences Inc. | Methods for genomic analysis |
| US6897025B2 (en) | 2002-01-07 | 2005-05-24 | Perlegen Sciences, Inc. | Genetic analysis systems and methods |
| US7135286B2 (en) | 2002-03-26 | 2006-11-14 | Perlegen Sciences, Inc. | Pharmaceutical and diagnostic business systems and methods |
| US7427480B2 (en) | 2002-03-26 | 2008-09-23 | Perlegen Sciences, Inc. | Life sciences business systems and methods |
| US20040210400A1 (en) | 2003-01-27 | 2004-10-21 | Perlegen Sciences, Inc. | Analysis methods for individual genotyping |
| US20040191783A1 (en) | 2003-03-31 | 2004-09-30 | Guy Leclercq | Low density micro-array analysis in human breast cancer |
| US20050019787A1 (en) | 2003-04-03 | 2005-01-27 | Perlegen Sciences, Inc., A Delaware Corporation | Apparatus and methods for analyzing and characterizing nucleic acid sequences |
| US7124033B2 (en) | 2003-04-30 | 2006-10-17 | Perlegen Sciences, Inc. | Method for identifying matched groups |
| US20040229224A1 (en) | 2003-05-13 | 2004-11-18 | Perlegen Sciences, Inc. | Allele-specific expression patterns |
| US20040241657A1 (en) | 2003-05-28 | 2004-12-02 | Perlegen Sciences, Inc. | Liver related disease compositions and methods |
| WO2005014846A2 (en) * | 2003-07-24 | 2005-02-17 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
| WO2005024067A2 (en) | 2003-09-04 | 2005-03-17 | Intergenetics, Inc. | Genetic analysis for stratification of breast cancer risk |
| US20090087854A1 (en) | 2007-09-27 | 2009-04-02 | Perlegen Sciences, Inc. | Methods for genetic analysis |
| US7127355B2 (en) | 2004-03-05 | 2006-10-24 | Perlegen Sciences, Inc. | Methods for genetic analysis |
| EP2468901B1 (en) | 2005-11-29 | 2017-04-05 | Cambridge Enterprise Limited | Markers for breast cancer |
| CA2656199A1 (en) | 2006-06-23 | 2007-12-27 | Intergenetics, Inc. | Genetic models for stratification of cancer risk |
| US20080131887A1 (en) | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
| EP2137324A2 (en) | 2007-03-26 | 2009-12-30 | Decode Genetics EHF | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |
| JP2010527603A (ja) | 2007-05-25 | 2010-08-19 | ディコーデ ジェネテクス イーエイチエフ | 乳癌のリスクアセスメント、診断、予後診断および治療における使用のためのマーカーとしてのＣＨＲ５ｐ１２および１０ｑ２６上の遺伝的変異 |
| CA2693783A1 (en) | 2007-07-11 | 2009-01-15 | Intergenetics, Inc. | Genetic models for stratification of cancer risk |
| WO2009097270A2 (en) * | 2008-01-28 | 2009-08-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of determining breast cancer risk |
| KR20110053995A (ko) | 2008-08-08 | 2011-05-24 | 네이비제닉스 인크. | 개인별 활동 계획을 위한 방법 및 체계 |
| GB2477868A (en) | 2008-09-12 | 2011-08-17 | Navigenics Inc | Methods and systems for incorporating multiple environmental and genetic risk factors |
| DK2438193T3 (en) | 2009-06-01 | 2015-10-19 | Genetic Technologies Ltd | Methods for assessing the risk of breast cancer |
| CA2766210A1 (en) * | 2009-06-25 | 2010-12-29 | Yale University | Single nucleotide polymorphisms in brca1 and cancer risk |
| WO2013151413A1 (en) * | 2012-04-02 | 2013-10-10 | Infovalley Life Science Sdn. Bhd. | Methods and compositions for determining increased risk for breast cancer |
| CA2962691C (en) | 2014-09-30 | 2023-05-23 | Genetic Technologies Limited | Methods for assessing risk of developing breast cancer |
| US20200102617A1 (en) | 2017-01-24 | 2020-04-02 | Genetic Technologies Limited | Improved Methods For Assessing Risk of Developing Breast Cancer |
| US10609708B1 (en) | 2017-06-27 | 2020-03-31 | Sprint Spectrum L.P. | Use of TDD special subframe for transmission of small quantity of data |
| CA3078756A1 (en) | 2017-10-13 | 2019-04-18 | Genetic Technologies Limited | Methods of assessing risk of developing breast cancer |
-
2015
- 2015-09-29 CA CA2962691A patent/CA2962691C/en active Active
- 2015-09-29 US US15/515,826 patent/US10920279B2/en not_active Expired - Fee Related
- 2015-09-29 EP EP15847907.1A patent/EP3201360A4/en not_active Withdrawn
- 2015-09-29 WO PCT/AU2015/050583 patent/WO2016049694A1/en not_active Ceased
- 2015-09-29 MX MX2017004127A patent/MX392267B/es unknown
- 2015-09-29 AU AU2015327756A patent/AU2015327756B2/en not_active Ceased
- 2015-09-29 IL IL251376A patent/IL251376B/en unknown
- 2015-09-29 CN CN201580063966.2A patent/CN107002138B/zh not_active Expired - Fee Related
- 2015-09-29 KR KR1020177014480A patent/KR102334702B1/ko not_active Expired - Fee Related
- 2015-09-29 JP JP2017517098A patent/JP6820838B2/ja not_active Expired - Fee Related
- 2015-09-29 SG SG11201702416YA patent/SG11201702416YA/en unknown
-
2016
- 2016-04-19 US US15/133,055 patent/US10683549B2/en active Active
-
2018
- 2018-03-29 AU AU2018202299A patent/AU2018202299B9/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529859A5 (enExample) | ||
| Fehlmann et al. | Evaluating the use of circulating microRNA profiles for lung cancer detection in symptomatic patients | |
| ES2962775T3 (es) | Método para predecir el pronóstico de pacientes con cáncer de mama | |
| JP7452894B2 (ja) | 遺伝子のｃｐｇメチル化変化を用いた肝癌の予後または危険度を評価する方法 | |
| Zhang et al. | Comprehensive one-step molecular analyses of mitochondrial genome by massively parallel sequencing | |
| JP2018505658A5 (enExample) | ||
| CA2978442A1 (en) | Methods for assessing the risk of disease occurrence or recurrence using expression level and sequence variant information | |
| Rodriguez-Reyna et al. | HLA class I and II blocks are associated to susceptibility, clinical subtypes and autoantibodies in Mexican systemic sclerosis (SSc) patients | |
| JP6606554B2 (ja) | Ｙ染色体のメチル化部位を前立腺ガンの診断用マーカとする使用 | |
| CN104178567B (zh) | 一种与乳腺癌辅助诊断相关的snp标志物及其应用 | |
| CN108323184A (zh) | 验证生物标志物测量 | |
| JP2019510473A5 (enExample) | ||
| JP2023527834A5 (enExample) | ||
| CN106591438A (zh) | 一种用于检测Her2基因的核酸组合、试剂盒及应用 | |
| CN106148529A (zh) | 与胃癌相关的LncRNA标记物及其专用检测引物、检测方法、试剂盒与应用 | |
| CN105603101A (zh) | 检测8个miRNA表达量的系统在制备诊断或辅助诊断肝细胞癌产品中的应用 | |
| TW201741915A (zh) | 基因表現圖譜以及將其應用於乳癌醫療之方法 | |
| Xin et al. | Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma | |
| CN104293919A (zh) | 一种与非吸烟女性肺癌辅助诊断相关的snp标志物及其应用 | |
| CN103911440B (zh) | 一种与铂类化疗药物肝脏毒性相关的snp标志物及其应用 | |
| JP5461959B2 (ja) | 神経膠腫予後予測方法、およびそれに用いるキット | |
| CN107653311B (zh) | 与血脂水平相关的单核苷酸多态性rs4883263检测系统及相关应用 | |
| WO2016066797A2 (en) | Ovarian cancer prognostic subgrouping | |
| US12371749B2 (en) | Molecular pathogenesis of microcarcinoma of the thyroid | |
| CN105087758A (zh) | 一种肺癌预后预测miRNA检测试剂盒 |